For instance, in 2022, a new initiative by McGill University’s Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.
The global dementia and Alzheimer’s disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer’s disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.
The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.
Major players operating in the global dementia and Alzheimer’s disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.
Objective of the Study
- To analyze and estimate the market size of global dementia and Alzheimer’sdisease treatment market from 2018 to 2021.
- To estimate and forecast the market size of global dementia and Alzheimer’sdisease treatment market from 2022 to 2028 and growth rate until 2028.
- To classify and forecast global dementia and Alzheimer’s diseasetreatment market based on drug class, distribution channel, company andregional distribution.
- To identify dominant region or segment in the global dementia and Alzheimer’sdisease treatment market.
- To identify drivers and challenges for global dementia and Alzheimer’s diseasetreatment market.
- To examine competitive developments such as expansions, new productlaunches, mergers & acquisitions, etc., in global dementia and Alzheimer’s diseasetreatment market.
- To conduct pricing analysis for global dementia and Alzheimer’s diseasetreatment market.
- To identify and analyze the profile of leading players operating inglobal dementia and Alzheimer’s disease treatment market.
- to identify key sustainable strategies adopted by market players inglobal dementia and Alzheimer’s disease treatment market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.
TechSci Research calculated the market size of
Key Target Audience
- Dementia and Alzheimer’sdisease treatment facilities and other stakeholders
- Government bodiessuch as regulating authorities and policy makers
- Organizations,forums and alliances related to dementia and Alzheimer’s disease treatment
- Market researchand consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
| Attribute | Details |
| Base Year | 2022 |
| Historical Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023E-2028F |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Drug Class Distribution Channel Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States, Mexico, Canada, China, India, Japan, South Korea, Australia; Germany, France, United Kingdom, Spain, Italy; South Africa, UAE, Saudi Arabia; Brazil, Argentina, Colombia; |
| Key companies profiled | Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc.. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
